Orchestra BioMed Holdings, Inc. (OBIO) Stock

Orchestra BioMed Holdings, Inc. (OBIO) is a Healthcare stock trading at $3.98 (as of 2026-06-18), with a market capitalization of $234.13M and a trailing P/E of -4.1. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Orchestra BioMed Holdings, Inc. is a biomedical innovation company focused on developing and commercializing medical therapies and devices. Its candidates include BackBeat Cardiac Neuromodulation Therapy for hypertension and Virtue Sirolimus AngioInfusion Balloon for atherosclerotic artery disease, alongside minimally invasive FreeHold retractors, with development and commercialization partnerships involving Medtronic and Terumo.

Valuation — source: SEC EDGAR (first-party)
Price	$3.98
Market Cap	$234.13M
P/E Ratio	-4.1
EV / EBITDA	-4.0
Price / Book	5.68
Price / Sales	7.15
DCF Value (model)	$-14.05
DCF Upside vs Price	-453.5%

Profitability & Growth — source: SEC EDGAR
Revenue (TTM)	$33.48M
Net Margin	-157.4%
Return on Equity	-132.6%
Debt / Equity	0.36
Current Ratio	7.03
Revenue Growth (YoY)	1169.2%
EPS Growth (YoY)	-33.1%
FCF Growth (YoY)	-2.7%

Financial Health — source: SEC EDGAR
Altman Z-Score	-2.39 (distress)
Piotroski F-Score	6/9 (moderate)

Valuation vs Sector & Industry
Stock P/E	-4.1
Sector P/E (Healthcare)	21.0
Industry P/E (Medical Equipment)	31.7
vs Sector	-119.6%
vs Industry	-113.0%

Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional Holder	RTW INVESTMENTS, LP ($35.30M)
Institutional Holders Tracked	10

Company
Sector	Healthcare
Industry	Medical Equipment
CEO	David Hochman
Employees	70
Country	US
IPO Date	2020-08-04

Related Companies (Business model: Medical Devices / Life Science Tools; 8 closest by market cap; US-domiciled)

Data as of 2026-06-18.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.